Suboxone Tooth Decay Lawsuit in Washington

Suboxone is a brand-name prescription medication containing buprenorphine and naloxone. It is FDA-approved for the treatment of opioid use disorder as part of a medication-assisted treatment (MAT) program. Suboxone works by partially activating opioid receptors (via buprenorphine) while blocking the euphoric effects of other opioids (via naloxone), reducing cravings and withdrawal symptoms without producing significant intoxication. It is typically prescribed by addiction medicine specialists, primary care physicians, and psychiatrists who hold a DEA waiver for buprenorphine prescribing. Millions of people in the United States use Suboxone or similar buprenorphine products as part of their recovery, and the medication is considered a lifesaving component of evidence-based addiction treatment.

Suboxone sublingual film contains citric acid and other acidic excipients added for formulation purposes. When the film strip dissolves under the tongue or against the cheek, it creates a highly acidic environment in the mouth with a pH that can fall to 3.4 to 4.0 — well below the threshold of approximately 5.5 at which tooth enamel begins to dissolve. Patients who take Suboxone multiple times daily over months or years are exposing their tooth enamel to repeated acid attacks. Over time, this acid erosion thins and softens enamel, making teeth highly vulnerable to rapid bacterial tooth decay. The result is often widespread, unusually fast-progressing cavities affecting multiple teeth simultaneously — a pattern dentists describe as consistent with acid erosion rather than ordinary dental caries.

Evidence strongly suggests that Indivior, the manufacturer of Suboxone, had access to information linking its sublingual film formulation to dental injuries years before updating its label. Case reports and medical literature documenting the association between buprenorphine sublingual formulations and dental decay began appearing as early as 2012. The FDA's Adverse Event Reporting System received reports of dental injuries in Suboxone users for years prior to the 2022 warning. Under pharmaceutical product liability law, manufacturers are required to monitor post-market safety data and update their labels when new risks are identified. The central claim in Suboxone dental injury litigation is that Indivior failed to fulfill this duty — that it knew or should have known about the dental risk and failed to warn patients and prescribers for over a decade.

The FDA issued its formal safety communication on January 12, 2022, titled "FDA warns about dental problems with buprenorphine medicines dissolved in the mouth." The agency reviewed 305 adverse event reports of dental injuries associated with buprenorphine medicines dissolved in the mouth, submitted to FAERS between product approval dates and October 2021. The FDA found the dental problems to be severe, including tooth decay, cavities, oral infections, tooth fractures, and tooth loss — some requiring extractions, root canals, and full dental reconstruction. The FDA required manufacturers, including Indivior, to add new warnings to prescribing information and patient medication guides. The January 12, 2022 date is legally significant because it is the point many courts may find that patients first had reasonable notice that Suboxone caused their dental injuries, potentially resetting the statute of limitations under the discovery rule.

Yes. The dental damage mechanism in Suboxone is not unique to the brand-name product — it results from the acidic excipients (primarily citric acid) present in sublingual buprenorphine film formulations generally. Generic buprenorphine/naloxone sublingual films, which entered the market after patent litigation in the mid-2010s, share similar formulation characteristics and have been associated with the same dental injury pattern. The January 2022 FDA safety communication specifically addressed "buprenorphine medicines dissolved in the mouth" broadly — not Suboxone alone. Patients who used generic buprenorphine/naloxone sublingual film and sustained dental injuries may have claims against the generic manufacturers under the same failure-to-warn theories, though the legal landscape for claims against generic manufacturers differs from brand-name claims in important ways. An attorney can evaluate the specific products used and applicable defendants.

Your dental damage is more likely to qualify if: (1) you used Suboxone sublingual film or a generic equivalent for at least six months; (2) you developed significant dental injuries — multiple cavities, tooth extractions, tooth loss, crowns, implants, or need for dental reconstruction — during or after your Suboxone use; (3) your dental injuries developed or accelerated during the period you were taking Suboxone; and (4) you have dental records that document the injuries and their timeline. Minor issues like a single cavity or routine sensitivity are generally not sufficient. The most compelling claims involve patients who had reasonably healthy teeth before starting Suboxone and then experienced rapid, widespread decay. A pharmaceutical litigation attorney can review your records and evaluate whether your specific situation meets the threshold for a viable claim.

The most important evidence for a Suboxone dental injury claim includes: (1) dental records from before, during, and after your Suboxone use — these establish the timeline and progression of your dental damage; (2) prescription records confirming your Suboxone use (including the start date, dosage, and duration) — your pharmacy can provide these; (3) medical records from your prescribing physician; (4) dental treatment records and billing documentation showing the procedures required and their costs; and (5) any written communications from your dentist or doctor connecting the damage to your medication. Dental X-rays are particularly valuable because they document the extent and progression of decay. You do not need to have all of this evidence in hand before contacting an attorney — a good pharmaceutical litigation attorney will help you gather the necessary records as part of the case evaluation process.

The value of a Suboxone dental injury claim depends primarily on the severity of dental damage, the cost of treatment required, and the impact on quality of life. Cases involving minor to moderate decay with restorable teeth typically fall in the $25,000 to $60,000 range. Cases involving multiple extractions and crown work typically range from $60,000 to $100,000. Cases requiring implants or significant reconstruction typically range from $100,000 to $135,000. Cases involving complete tooth loss and full-mouth reconstruction can reach $125,000 to $200,000 or more. These estimates reflect reported settlements and litigation expectations; the Suboxone MDL (MDL 3092) is ongoing and no global settlement has been announced. Economic damages (actual dental treatment costs) and non-economic damages (pain, suffering, psychological impact, and quality of life) are both recoverable.

Suboxone dental injury litigation is structured as a multidistrict litigation (MDL), not a traditional class action. MDL 3092, In re: Suboxone (Buprenorphine Hydrochloride and Naloxone) Sublingual Film Products Liability Litigation, is pending in the Northern District of Ohio. In an MDL, cases from across the country are consolidated for pretrial proceedings — primarily discovery and motions practice — before a single federal judge. Each plaintiff retains their individual claim and their own damages. This is different from a class action, where all plaintiffs share a single recovery. The MDL process allows plaintiffs to benefit from consolidated discovery of Indivior's internal documents and company-wide expert witnesses, while preserving each individual's right to recovery based on their specific injuries. After pretrial proceedings conclude (or if a global settlement is reached), individual cases are resolved either through settlement or returned to their home districts for trial.

No. You do not need to stop taking Suboxone or any other MAT medication to pursue a legal claim. Your medical treatment decisions should be made with your healthcare provider based solely on what is best for your health and recovery. A lawsuit is a separate civil proceeding that does not affect your medical care. In fact, the FDA's January 2022 safety communication explicitly states that patients should not stop taking buprenorphine medicines without first talking to their healthcare provider, noting that the risks of untreated opioid use disorder are serious. Your attorney will advise you on mitigation steps you can take going forward — such as rinsing after each dose — but these steps do not require stopping the medication. Your recovery is the priority.

Economic damages include: past dental treatment costs (fillings, extractions, implants, crowns, bridges, bone grafting, full-mouth reconstruction); future dental treatment costs; any lost wages if dental appointments or complications required missing work; and out-of-pocket prescription or health insurance costs. Non-economic damages include: pain and suffering from dental procedures and dental disease; emotional distress; psychological harm including depression, anxiety, and reduced self-esteem resulting from tooth loss; social and functional limitations caused by tooth loss (difficulty eating, speaking, smiling); and loss of enjoyment of life. In cases where Indivior's conduct is found to be particularly egregious, punitive damages may also be available.

The statute of limitations for Suboxone dental injury claims varies by state and typically ranges from 2 to 3 years from the date you knew or should have known that Suboxone caused your dental injuries. Critically, many plaintiff attorneys argue that the statute of limitations should begin from January 12, 2022 — the date of the FDA's formal safety communication — because that is the first time patients received official notice connecting Suboxone to dental injuries. If that analysis applies to your state, claims filed before January 12, 2024 (for 2-year states) or January 12, 2025 (for 3-year states) would be timely. Some states may have already passed their 2-year window if the FDA notice rule applies. Do not rely on these general estimates — individual state laws vary, and specific facts about when you discovered or should have discovered the connection can dramatically affect your deadline. Consult a pharmaceutical litigation attorney immediately to determine the deadline applicable to your claim.